Grace Therapeutics Files 8-K on Shareholder Matters
Ticker: GRCE · Form: 8-K · Filed: Sep 12, 2025 · CIK: 1444192
| Field | Detail |
|---|---|
| Company | Grace Therapeutics, INC. (GRCE) |
| Form Type | 8-K |
| Filed Date | Sep 12, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, shareholder-meeting, disclosure
TL;DR
Grace Therapeutics filed an 8-K for shareholder votes - could be big.
AI Summary
Grace Therapeutics, Inc. filed an 8-K on September 12, 2025, to report on matters submitted to a vote of its security holders. The company, formerly known as Acasti Pharma Inc., is incorporated in Delaware and headquartered in Princeton, New Jersey.
Why It Matters
This filing indicates that Grace Therapeutics held a meeting or took action requiring a vote from its shareholders, which could pertain to corporate governance, financing, or strategic decisions.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote, not an indication of immediate financial distress or significant operational change.
Key Numbers
- 001-35776 — SEC File Number (Identifies the company's filing history with the SEC.)
- 0001444192 — Central Index Key (Unique identifier for the company in the SEC's EDGAR system.)
Key Players & Entities
- Grace Therapeutics, Inc. (company) — Registrant
- Acasti Pharma Inc. (company) — Former Name
- September 12, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Princeton, New Jersey (location) — Principal Executive Offices
FAQ
What specific matters were submitted to a vote of Grace Therapeutics' security holders?
The filing does not specify the exact matters voted upon, only that Item 5.07 is being reported, which pertains to the submission of matters to a vote of security holders.
When was the former name 'Acasti Pharma Inc.' officially changed?
The filing indicates the date of the name change from Acasti Pharma Inc. to Grace Therapeutics, Inc. was August 28, 2008.
What is Grace Therapeutics' primary business classification?
Grace Therapeutics, Inc. is classified under Standard Industrial Classification (SIC) code 2834, which is 'Pharmaceutical Preparations'.
Where are Grace Therapeutics' principal executive offices located?
The principal executive offices are located at 103 Carnegie Center, Suite 300, Princeton, New Jersey, 08540.
What is the fiscal year end for Grace Therapeutics?
The fiscal year end for Grace Therapeutics, Inc. is March 31.
Filing Stats: 691 words · 3 min read · ~2 pages · Grade level 13.5 · Accepted 2025-09-12 16:13:10
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share GRCE The Nasdaq Stock Mar
Filing Documents
- ef20055483_8k.htm (8-K) — 40KB
- 0001140361-25-034845.txt ( ) — 165KB
- grce-20250912.xsd (EX-101.SCH) — 4KB
- grce-20250912_lab.xml (EX-101.LAB) — 21KB
- grce-20250912_pre.xml (EX-101.PRE) — 16KB
- ef20055483_8k_htm.xml (XML) — 4KB
07
Item 5.07 Submission of Matters to a Vote of Security Holders. On September 12, 2025, Grace Therapeutics, Inc. (the "Company") held its Annual Meeting of Stockholders (the "Meeting"). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended, and there was no solicitation in opposition to the Company's board of director's solicitation. Stockholders of a total of 7,926,945 of the Company's shares of common stock were present or represented by proxy at the Meeting, representing 57.32% of the Company's 13,828,562 shares of common stock issued and outstanding and entitled to vote at the Meeting as of the record date of July 18, 2025. Set forth below are the matters acted upon by the Company's stockholders at the Meeting and the final voting results on each matter. Each of the proposals is described in further detail in the Proxy Statement. Proposal No. 1 – Election of Directors The nominees listed below were elected as directors by the following votes to serve until the close of the Company's next annual meeting of stockholders and until such director's successor is elected and qualified or until his earlier death, resignation, retirement, disqualification or removal: Nominee Votes For Withheld Broker Non-Votes Vimal Kavuru 6,294,270 34,185 1,598,490 A. Brian Davis 6,299,935 28,520 1,598,490 Prashant Kohli 6,299,420 29,035 1,598,490 S. George Kottayil 6,300,168 28,287 1,598,490 Edward Neugeboren 6,300,263 28,192 1,598,490 Proposal No. 2 – Advisory Vote to Approve Named Executive Officer Compensation The proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the Company's proxy statement was approved by the stockholders by the following vote: For Against Abstain Broker Non-Votes 6,178,757 74,002 75,696 1,598,490 Proposal No. 3 – Ratify the Appointment of Independent Registered Public Accounting Firm The propos
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: September 12, 2025 GRACE THERAPEUTICS, INC. By: /s/ Prashant Kohli Name: Prashant Kohli Title: Chief Executive Officer